Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Open accessThe DOI matches its Crossref record; 71 of the 73 references it cites were found in a registry or an index.
Abstract
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain barrier and systemic adverse effects. Intranasal administration offers a direct route to the brain via the nasal cavity’s olfactory and trigeminal pathways. However, nasal physiology can hinder drug absorption and limit bioavailability. Therefore, the physicochemical characteristics of formulations must be optimized by means of technological strategies. Among the strategies that have been explored, lipid-based nanosystems, particularly nanostructured lipid carriers, are promising in preclinical investigations with minimal toxicity and therapeutic efficacy due to their ability to overcome challenges associated with other nanocarriers. We review the studies of nanostructured lipid carriers for intranasal administration in the treatment of ATD. Currently, no drugs for intranasal administration in ATD have marketing approval, with only three candidates, insulin, rivastigmine and APH-1105, being clinically investigated. Further studies with different candidates will eventually confirm the potential of the intranasal route of administration in the treatment of ATD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 7 Innervation of the trigeminal nerve in the nasal cavity [39].](https://figures.cochat.ai/paper-figures/fd7eb22a56924927b531540e24dc7c54/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-7.jpg)


![Figure 3 (a) Anatomy of the nasal cavity, adapted from [32]. (b) Schematic representation of the olfactory region, adapted from [33].](https://figures.cochat.ai/paper-figures/6da7e5797e14487bb33d26eefca756c0/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-3.jpg)
![Figure 4 Factors affecting absorption through the nasal route [34].](https://figures.cochat.ai/paper-figures/688df23c98974d99bc31b371dfbc1de1/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-4.jpg)
![Figure 5 Mechanisms of drug absorption across the nasal epithelium [32].](https://figures.cochat.ai/paper-figures/938fb1209c844be380aea1ff4b583526/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-5.jpg)
![Figure 6 Intranasal transport of drugs through the olfactory route to the CNS by intracellular and extracellular routes [36].](https://figures.cochat.ai/paper-figures/01baa9b26e15440b8c7d6a51c5740cd5/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-6.jpg)
![Figure 8 Schematic representation of the structure of the nasal cavity and the mechanisms of drug absorption through the nasal mucosa to the brain. (A) Direct absorption mechanism through olfactory nerve and trigeminal route. (B) Indirect absorption mechanism by systemic route [42].](https://figures.cochat.ai/paper-figures/b5c3ba1682fd4acab06b49ecce101d7b/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-8.jpg)
![Figure 9 Lipid-based nanocarriers that have been explored for drug access to the brain from the nasal route [62].](https://figures.cochat.ai/paper-figures/3b2a6127a13e497fb48f67499281c055/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-9.jpg)
![Figure 10 Main differences between solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLCs) [66].](https://figures.cochat.ai/paper-figures/9c610ddcff6e4d19aa6dd9ab70cc3c29/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-10.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanocarriers play a crucial role in increasing drug concentrations, slowing drug release, and achieving excellent bioavailability.401,406,407”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [406]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · cited 2×
“There were over 50 million ATD cases globally as of 2020 [4].”
BackgroundStrategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138 · cited 1×
“The BBB is a complex structure made up of endothelial cells sealed by tight junctions, pericytes, basement membrane and astrocytes that create a continuous barrier [24].”
BackgroundBurns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859 · cited 1×
“Around 6% of adults 65 and older are affected, with women being more frequently affected than males [9].”
BackgroundCilia and Mucociliary Clearance
Bustamante-Marin, X. M., & Ostrowski, L. E. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028241 · Cited by 830 · cited 1×
“When a formulation is administered via the nose, it has to go through mucociliary clearance, which will eliminate a part of the drug and which, together with the short residence time of the drug in the nasal cavity, will limit its absorption through the mucosa [44].”
BackgroundEvaluation of intranasal delivery route of drug administration for brain targeting
Erdő, F., Bors, L. A., Farkas, D., Bajza, Á., & Gizurarson, S. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.10.009 · Cited by 744 · cited 3×
“Intranasal transport of drugs through the olfactory route to the CNS by intracellular and extracellular routes [36].”
BackgroundInfluentialGlobal, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
Li, X., Feng, X., Sun, X., Hou, N., Han, F., & Liu, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.937486 · Cited by 703 · cited 3×
“Dementia is more common in some parts of the world than others, with a prevalence of 4.7% in Central Europe and an 8.7% prevalence in North Africa and the Middle East [5,6].”
BackgroundInfluentialAgrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630 · cited 1×
“In addition, systemic administration may present other limitations such as binding to plasma proteins, low volume of distribution, delay in drug delivery to the brain through the blood, and systemic adverse effects, especially at the gastrointestinal level (such as nausea and vomiting) [21].”
BackgroundThe discovery of Alzheimer's disease
Hippius, H., & Neundörfer, G. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/hhippius · Cited by 516 · cited 2×
“e disease is named Alzheimer’s disease in h n r of Alois Alzheimer, a German psychiatrist and pathologist, who in 1906, first describ d th case of a 50-year-old woman with pr senile dementia [10].”
BackgroundClinical translation of nanomedicines: Challenges, opportunities, and keys
Younis, M. A., Tawfeek, H. M., Abdellatif, A. A. H., Abdel-Aleem, J. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114083 · Cited by 462 · cited 1×
“Finally, the lack of widely accepted international standards for regulating nanomedicines also poses a challenge [83].”
BackgroundNanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review
Haider, M., Abdin, S. M., Kamal, L., & Orive, G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030288 · Cited by 451 · cited 1×
“There are several types of lipid-based nanocarriers, such as liposomes [56], niosomes [57,58], microemulsions [59], nanoemulsions [60] and solid-matrix lipid nanoparticles [61] as shown in Figure 9.”
BackgroundDando, S. J., Mackay-Sim, A., Norton, R., Currie, B. J., St. John, J. A., Ekberg, J. A. K., Batzloff, M., Ulett, G. C., & Beacham, I. R. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00118-13 · Cited by 428 · cited 1×
“(b) Schematic representation of the olfactory region, adapted from [33].”
BackgroundRecent advances in carrier mediated nose-to-brain delivery of pharmaceutics
Bourganis, V., Kammona, O., Alexopoulos, A., & Kiparissides, C. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.05.009 · Cited by 357 · cited 2×
“In addition, transcellular diffusion is the main transport mechanism from the nose to the brain, which mainly allows the passage of lipophilic and low molecular weight substances [40].”
BackgroundCraft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335 · cited 1×
“The ViaNase® device was used in the clinical trial of intranasal insulin delivery for the treatment of ATD [47].”
MethodNiosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier
Gharbavi, M., Amani, J., Kheiri-Manjili, H., Danafar, H., & Sharafi, A. (2018) · Advances in Pharmacological Sciences · doi:10.1155/2018/6847971 · Cited by 287 · cited 1×
“There are several types of lipid-based nanocarriers, such as liposomes [56], niosomes [57,58], microemulsions [59], nanoemulsions [60] and solid-matrix lipid nanoparticles [61] as shown in Figure 9.”
BackgroundStrategies to Enhance Drug Absorption via Nasal and Pulmonary Routes
Ghadiri, M., Young, P. M., & Traini, D. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030113 · Cited by 284
Wang, Z., Xiong, G., Tsang, W. C., Schätzlein, A. G., & Uchegbu, I. F. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258152 · Cited by 231 · cited 1×
“Several delivery devices have been developed (listed in Table 3), of which only the Optinose®, Precision Olfactory Delivery® and ViaNase® devices have been used in studies of intranasal administration to the brain in humans [46].”
MethodAgrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Patel, R. J., Ajazuddin, Ravichandiran, V., Murty, U. S., & Alexander, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.020 · Cited by 230 · cited 1×
“For this reason, current research focuses on NLCs [64,65].”
BackgroundNanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies
Pires, P. C., & Santos, A. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.047 · Cited by 228 · cited 1×
“Administration by nasal drops achieves maximum exposure to the respiratory region, directing the drug to the systemic circulation and to the pulmonary organs, while the administration of the formulation with the head inclined upwards with suitable devices ensures maximum focus on the olfactory region, facilitating the…”
BackgroundTreatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers
Poovaiah, N., Davoudi, Z., Peng, H., Schlichtmann, B., Mallapragada, S., Narasimhan, B., & Wang, Q. (2018) · Nanoscale · doi:10.1039/c8nr04073g · Cited by 225 · cited 1×
“Transcellular diffusion is the main mechanism of absorption and is the most suitable for lipophilic and low molecular weight molecules [26,35].”
BackgroundKales, H. C., Lyketsos, C. G., Miller, E. M., & Ballard, C. (2019) · International Psychogeriatrics · doi:10.1017/s1041610218000534 · Cited by 220 · cited 1×
“Astaxanthin (AST) is a second-generation antioxidant with anti-inflammatory and neuroprotective properties and could be a promising candidate for Alzheimer’s disease (AD) therapy, but is shows poor oral bioavailability due to its high lipophilicity [80].”
BackgroundSelvaraj, K., Gowthamarajan, K., & Karri, V. V. S. R. (2017) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2017.1420073 · Cited by 210 · cited 2×
“The intracellular route requires from hours to days for the active fraction to reach the different regions of the brain and is adequate for the passage of lipophilic molecules, while the extracellular route only requires a few minutes for the active fraction to reach the brain and is suitable for the passage of hydrop…”
BackgroundNose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis
Costa, C., Moreira, J. N., Amaral, M. H., Sousa Lobo, J. M., & Silva, A. C. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.049 · Cited by 210 · cited 2×
“Likewise, NLCs o fer advantages over ot er s ste s f r , since t can be manufactured from biocompatible and biodegr dable compo ents, such as physiological lipids and other GRAS (Generally Recognized As Safe) excipients [67].”
BackgroundNanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier
Lee, D., & Minko, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122049 · Cited by 209 · cited 1×
“In addition, the olfactory region facilitates the transport of drugs to the brain having a direct connection with the brain through the olfactory and trigeminal neurons [31].”
BackgroundLiposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198 · cited 1×
“There are several types of lipid-based nanocarriers, such as liposomes [56], niosomes [57,58], microemulsions [59], nanoemulsions [60] and solid-matrix lipid nanoparticles [61] as shown in Figure 9.”
BackgroundNasal route for vaccine and drug delivery: Features and current opportunities
Lobaina, Y. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118813 · Cited by 171 · cited 1×
“In addition, the respiratory region is innervated by the maxillary and ophthalmic branches of the trigeminal nerve (V1, V2) [30].”
BackgroundIntranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders
Bahadur, S., Pardhi, D. M., Rautio, J., Rosenholm, J. M., & Pathak, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121230 · Cited by 170 · cited 2×
“Transport through the trigeminal route can also oc ur intracellularly or extracellularly, as occurs with olfactory neurons [38].”
BackgroundEarly-onset Alzheimer's Disease: Nonamnestic Subtypes and Type 2 AD
Mendez, M. F. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.11.009 · Cited by 166 · cited 1×
“Although up to 10% of cases have an early beginning and affect people in their 30s to mid-60s, adults over 65 years old account for the majority of cases [7,8].”
BackgroundLiposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives
Hong, S.-S., Oh, K. T., Choi, H.-G., & Lim, S.-J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11100540 · Cited by 162 · cited 1×
“Likewise, it is necessary to consider the appropriate selection of excipients, the physicochemical properties (particle size, size distribution, zeta potential and drug charge), biodegradability, biocompatibility, the release profile and also the safety profile [54].”
BackgroundCunha, S., Forbes, B., Sousa Lobo, J. M., & Silva, A. C. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s305851 · Cited by 144 · cited 3×
“For this reason, it is essential to develop detailed nanotoxicological studies to identify the specific elements that guarantee its safety, such as the biological compatibility of the formulation components, the effect of particle size and surface charge [42].”
BackgroundInfluentialLipid Nanoparticles for Nasal/Intranasal Drug Delivery
Cunha, S., Amaral, M. H., Lobo, J. M. S., & Silva, A. C. (2017) · Critical Reviews™ in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2017018693 · Cited by 138 · cited 2×
“SLNs present a lipid matrix composed of a single solid lipid that has a highly organized structure and are nsider the first eneration of lipid nanoparticles, while NLCs present a disorganized internal lipid matrix, formed by a mixture of solid and liquid lipids and are known as second-generation lipid nanoparticles [6…”
BackgroundNguyen, T.-T.-L., & Maeng, H.-J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030572 · Cited by 130
Lipid Nanoparticles and Their Hydrogel Composites for Drug Delivery: A Review
Desfrançois, C., Auzély, R., & Texier, I. (2018) · Pharmaceuticals · doi:10.3390/ph11040118 · Cited by 122
Gadhave, D. G., & Kokare, C. R. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1576724 · Cited by 117 · cited 1×
“3 and a zeta potential (ZP) of 30 mV [68].”
BackgroundProgress and Current Trends in the Synthesis of Novel Polymers with Enhanced Mucoadhesive Properties
Brannigan, R. P., & Khutoryanskiy, V. V. (2019) · Macromolecular Bioscience · doi:10.1002/mabi.201900194 · Cited by 116 · cited 1×
“, which favor nasal absorption of drugs as a result of increased residence time in the area of administration, can be used [45].”
BackgroundRajput, A. P., & Butani, S. B. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.01.040 · Cited by 113 · cited 2×
“formulated an in situ gel to incorporate resveratrolloaded NLCs for administration from the nose to the brain [77].”
BackgroundHallschmid, M. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12934 · Cited by 113 · cited 1×
“This is due to the fact that insulin influences the production and elimination of the Aβ peptide and also prevents tau hyperphosphorylation, among other effects relevant to ATD [88].”
BackgroundJojo, G. M., Kuppusamy, G., De, A., & Karri, V. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1593439 · Cited by 111 · cited 2×
“6 Increased bioavailability Nose–brain direct delivery [75] 2019”
BackgroundIn vitro Alternatives to Acute Inhalation Toxicity Studies in Animal Models—A Perspective
Movia, D., Bruni-Favier, S., & Prina‐Mello, A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00549 · Cited by 109 · cited 1×
“Toxicity is often exacerbated by the use of polymers, mucoadhesive agents or any other novel approach that can dramatically increase the contact time of the mucosal layer with the drug to increase its absorption across the nasal epithelium [51].”
BackgroundAkel, H., Ismail, R., & Csóka, I. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.12.014 · Cited by 107 · cited 3×
“All these characteristics make it difficult to obtain bioavailability into the brain via the intranasal route [29].”
BackgroundInfluentialTreatment of Alzheimer’s diseases using donepezil nanoemulsion: an intranasal approach
Kaur, A., Nigam, K., Bhatnagar, I., Sukhpal, H., Awasthy, S., Shankar, S., Tyagi, A. K., & Dang, S. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00754-z · Cited by 106 · cited 1×
“There are several types of lipid-based nanocarriers, such as liposomes [56], niosomes [57,58], microemulsions [59], nanoemulsions [60] and solid-matrix lipid nanoparticles [61] as shown in Figure 9.”
BackgroundWavikar, P., Pai, R. V., & Vavia, P. R. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.08.024 · Cited by 104 · cited 2×
“3 brain concentration Increased bioavailability Improves memory and cognition No or very little nasal toxicity [72] 2017”
BackgroundMethodLipid Nanocarriers Overlaid with Chitosan for Brain Delivery of Berberine via the Nasal Route
El-Enin, H. A. A., Elkomy, M. H., Naguib, I. A., Ahmed, M. F. E., Alsaidan, O. A., Alsalahat, I., Ghoneim, M. M., & Eid, H. M. (2022) · Pharmaceuticals · doi:10.3390/ph15030281 · Cited by 104 · cited 1×
“developed a formulation of BER-loaded chitosan-coated NLCs for intranasal administration [79].”
BackgroundAgrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S.-D., Chougule, M., Shoyele, S. A., Gupta, U., Ajazuddin, et al. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1471058 · Cited by 101 · cited 1×
“For this reason, current research focuses on NLCs [64,65].”
BackgroundIntranasal drug delivery for treatment of Alzheimer’s disease
Fonseca, L., Lopes, J. A., Vieira, J., Viegas, C., Oliveira, C. S., Hartmann, R. P., & Fonte, P. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00940-7 · Cited by 100
Akbar, M., Shabbir, A., Rehman, K., Akash, M. S. H., & Shah, M. A. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13936 · Cited by 100 · cited 1×
“Recent research has shown that the isoquinoline alkaloid berberine (BER) may be effective in the treatment of ATD as it inhibits the formation of ß-amyloid plaques, decreases tau hyperphosphorylation and reduces oxidative stress [78].”
BackgroundPokharkar, V., Patil-Gadhe, A., & Palla, P. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.067 · Cited by 96 · cited 1×
“Lipid-based nanocarriers can incorporate both hydrophilic and lipophilic drugs, provide protection and offer controlled drug release by immobilizing the drug in the solid lipid matrix, which biodegrades easily [55].”
BackgroundEvaluation of Rivastigmine in Alzheimer’s Disease
Nguyen, K., Hoffman, H., Chakkamparambil, B., & Grossberg, G. T. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0052 · Cited by 89 · cited 1×
“causing the side effects of accumulation at a systemic level [71].”
BackgroundKulkarni, P., Rawtani, D., & Barot, T. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.02.015 · Cited by 86 · cited 1×
“There are several types of lipid-based nanocarriers, such as liposomes [56], niosomes [57,58], microemulsions [59], nanoemulsions [60] and solid-matrix lipid nanoparticles [61] as shown in Figure 9.”
BackgroundShehata, M. K., Ismail, A. A., & Kamel, M. A. E.-N. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s402447 · Cited by 80 · cited 3×
“(2023) [81] prepare and evaluate AST-loaded nanostructured lipid carriers (NLCs) for enhanced nose-to-brain drug delivery to improve the therapeutic efficacy in a rat model of AD.”
BackgroundMethodInfluentialRiccardi, C., Napolitano, F., Montesarchio, D., Sampaolo, S., & Melone, M. A. B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111897 · Cited by 75 · cited 3×
“Small lipophilic molecules and certain essential nutrients can pass through the blood–brain barrier (BBB) via passive diffusion (both paracellular and transcellular pathways) or through active transport mechanisms [26].”
BackgroundNeuroprotective effects of resveratrol in Alzheimer rsquo s disease
Murlimanju, B. V. (2019) · Frontiers in Bioscience-Elite · doi:10.2741/e863 · Cited by 67 · cited 1×
“However, it exhibits poor aqueous solubility and chemical stability, along with high firstpass metabolism, which contributes to poor bioavailability after oral administration [76].”
BackgroundVillarejo‐Galende, A., Ortiz, M. E., Velasco, S. L., Luque, M. L., de Miguel, C. L. D. S., & Jurczynska, C. P. (2019) · Neurología (English Edition) · doi:10.1016/j.nrleng.2017.10.004 · Cited by 66
Reassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
Insulin mediated novel therapies for the treatment of Alzheimer's disease
Dubey, S. K., Lakshmi, K. K., Krishna, K. V., Agrawal, M., Singhvi, G., Saha, R. N., Saraf, S., Saraf, S., Shukla, R., & Alexander, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117540 · Cited by 60 · cited 1×
“s ca e see , st f t e trials it i acti e c s t at ca e a i istere through the nose to treat ATD stop at their preclinical phase, and only three candidates have managed to reach the clinical investigation phase, namely insulin [84], rivastigmine [85] and APH-1105 [86].”
BackgroundBinda, A., Murano, C., & Rivolta, I. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231480 · Cited by 60 · cited 1×
“However, none of these drugs can prevent the progression of the disease, but instead act by temporarily increasing cognitive functions through a partial improvement of cholinergic and glutamic neurotransmission [18].”
BackgroundInforme de la Fundación del Cerebro. Impacto social de la enfermedad de Alzheimer y otras demencias
Villarejo Galende, A., Eimil Ortiz, M., Llamas Velasco, S., Llanero Luque, M., López de Silanes de Miguel, C., & Prieto Jurczynska, C. (2021) · Neurología · doi:10.1016/j.nrl.2017.10.005 · Cited by 55
An Overview on Topical Administration of Carotenoids and Coenzyme Q10 Loaded in Lipid Nanoparticles
Guedes, L. D. S., Martinez, R. M., Bou‐Chacra, N. A., Velasco, M. V. R., Rosado, C., & Baby, A. R. (2021) · Antioxidants · doi:10.3390/antiox10071034 · Cited by 55 · cited 1×
“Main differences between solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLCs) [66].”
BackgroundLipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders
Nguyen, T. T., Nguyen, T. T. D., An, T. N. M., & Giau, V. V. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03488-7 · Cited by 55 · cited 1×
“Lipid-based nanocarriers that have been explored for drug access to the brain from the nasal route [62].”
BackgroundAntidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges
Vitorino, C., Silva, S., Bicker, J., Falcão, A. C., & Fortuna, A. C. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.001 · Cited by 48 · cited 1×
“In addition, they allow drugs to be protected from chemical or metabolic degradation and improve solubility or transport through biological membranes, leading to better orientation and fewer systemic adverse effects [53].”
BackgroundPrabakaran, A., Agrawal, M., Dethe, M. R., Ahmed, H., Yadav, A. K., Gupta, U. D., & Alexander, A. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2029845 · Cited by 48 · cited 2×
“In addition, among the main biomarkers of ATD are the dep sition of the ß-amyloid peptide, which leads to the formation of ß-amyloid plaques, and the hyperphosphorylation of tau, which leads to the formation of neurofibrillary tangles [11].”
Backgroundde Souza, I. F. F., dos Santos, T. Q., Plácido, R. V., Mangerona, B. A., Carvalho, F. C., Boralli, V. B., Ruela, A. L. M., & Pereira, G. R. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111721 · Cited by 38 · cited 1×
“There are several types of lipid-based nanocarriers, such as liposomes [56], niosomes [57,58], microemulsions [59], nanoemulsions [60] and solid-matrix lipid nanoparticles [61] as shown in Figure 9.”
BackgroundChallenges in Nasal Drug absorption: How Far have We come?
Agu, R. U. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0022 · Cited by 37 · cited 2×
“Mechanisms of drug absorption across the nasal epithelium [32].”
BackgroundAnand, A., Arya, M., Kaithwas, G., Singh, G., & Saraf, S. A. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.11.021 · Cited by 36 · cited 2×
“8% Controlled and sustained release of 80% of the drug for 12 h Controlled diffusion, initially through surface erosion Significant reduction in AChE1 and AchE2 activity, which enhances neuronal function Significant improvement of memory, learning and cognitive response [73] 2019”
BackgroundNose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders
Bicker, J., Fortuna, A. C., Alves, G., & Falcão, A. C. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200115101544 · Cited by 36 · cited 1×
“It also leads to a higher incidence of unwanted side effects in other peripheral organs [41].”
BackgroundNano-lipidic formulation and therapeutic strategies for Alzheimer’s disease via intranasal route
Tripathi, S., Gupta, U., Ujjwal, R. R., & Yadav, A. K. (2021) · Journal of Microencapsulation · doi:10.1080/02652048.2021.1986585 · Cited by 26 · cited 1×
“In addition, it is responsible for maintaining an optimal ion composition for neuronal signaling [25].”
BackgroundDhas, N. L., Kudarha, R. R., & Mehta, T. A. (2018) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2018026762 · Cited by 24 · cited 2×
“However, other physicochemical properties of the drug and the formulation must also be considered, as well as some physiological factors of the nose, which may also influence the bioavailability and transport of the drug from the nose to the brain [34].”
BackgroundTariot, P. N., Braeckman, R., & Oh, C. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220530 · Cited by 24 · cited 3×
“Donepezil Oral Tablets Orodispersible tablets [12,13,22] Transdermal Transdermal patches Combination of memantine and donepezil Oral Controlled release capsules [23]”
BackgroundInfluentialSafety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine
Bakker, C., van der Aart, J., Hart, E. P., Klaassen, E. S., Bergmann, K. R., van Esdonk, M. J., Kay, D. G., & Groeneveld, G. J. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12093 · Cited by 23 · cited 1×
“However, some adverse effects related to the gastrointestinal tract and nasal mucosal irritation, both dose-dependent, were reported, which were the cause of withdrawal in some subjects [50].”
BackgroundMorgan, T. M., & Soh, B. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13133 · Cited by 12 · cited 1×
“s ca e see , st f t e trials it i acti e c s t at ca e a i istere through the nose to treat ATD stop at their preclinical phase, and only three candidates have managed to reach the clinical investigation phase, namely insulin [84], rivastigmine [85] and APH-1105 [86].”
BackgroundConsiderations When Developing Blood–Brain Barrier Crossing Drug Delivery Technology
Bell, R. D. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_453 · Cited by 2
Research works printed but not linked: 1
- Rajput, 2018, Fabrication of an ion-sensitive in situ gel loaded with nanostructured lipid carrier for nose to brain delivery of donepezil, Asian J. Pharm., 12, 293
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“401,406,407 Furthermore, the combination use of appropriate cholinesterase inhibitors, such as donepezil ( 4 ) and galantamine ( 6 ), or the combination of cholinesterase inhibitors with other neurologic drugs, metal chelators, or antioxidants, may yield surprising effects in the management of…”
BackgroundHuang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Mitochondria-Targeted Delivery Strategy of Dual-Loaded Liposomes for Alzheimer’s Disease Therapy
Vasileva, L. A., Gaynanova, G. A., Valeeva, F. G., Belyaev, G. P., Zueva, I. V., Bushmeleva, K., Sibgatullina, G., Samigullin, D., Vyshtakalyuk, A. B., Petrov, K. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310494 · Cited by 51
Biomaterial strategies for regulating the neuroinflammatory response
Galindo, A. N., Rubio, D. A. F., & Hettiaratchi, M. H. (2024) · Materials Advances · doi:10.1039/d3ma00736g · Cited by 50
Peng, D., Liu, T., Lu, H., Zhang, L., Chen, H., Huang, Y., Hu, B., & Zhang, Q. (2024) · Theranostics · doi:10.7150/thno.103596 · Cited by 54
Metadata
- Authors
- Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A.
- Affiliations
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain
- Molecular Topology and Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain
- Universitat de València (ES)
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-05-03
- Volume
- 15
- Issue
- 5
- Pages
- 1399
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC10223127
- OpenAlex
- W4378516181
- Cited by
- 59
- References
- 73
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 19 · 2023: 6
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- intranasal administration, Alzheimer-type dementia, nanostructured lipid carriers, lipid-based nanosystems, blood-brain barrier, intranasal drug delivery, drug bioavailability, nanocarriers, rivastigmine, insulin, Alzheimer's disease treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.